Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vincerinone in Friedreich's Ataxia with Point Mutations
NCT01962363Phase 2Completed
- Sponsor
- University of South Florida
- Start
- Oct 2013
- Primary completion
- Jun 2016
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vatiquinone in Friedreich's ataxia (FA), sponsored by University of South Florida. Primary endpoints: Visual function at 3 months and Safety parameters at 3 months. Started Oct 2013; status: completed.
02
Drugs
vatiquinone
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT01962363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01962363.